Co-diagnostics, inc. logix smart™ covid-19 2-gene test approved for use in the united kingdom

Salt lake city, nov. 4, 2021 /prnewswire/ -- co-diagnostics, inc. (nasdaq: codx), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that its logix smart™ sars-cov-2 2-gene multiplex test has been validated according to the united kingdom health security agency's ("ukhsa") medical devices (coronavirus test device approvals) (amendment) regulations 2021 ("ctda") and is available for sale in the uk under the regulation. the ukhsa is the agency responsible for planning, preventing, and responding to external health threats, replacing public health england earlier this year.
CODX Ratings Summary
CODX Quant Ranking